Abbie Celniker has more than 30 years of experience in senior R&D and executive leadership roles. As partner at Third Rock Ventures, she focuses on the formation, development and strategy of portfolio companies. She has a strong commitment to culture, and prioritizes establishing experienced, diverse teams.
Prior to Third Rock, Abbie served as president and CEO of Eleven Biotherapeutics (now Sesen Bio) since 2011. Previously, Abbie was the president and CEO of Taligen Therapeutics from 2008 to 2011, when Taligen Therapeutics was acquired by Alexion Pharmaceuticals; following the acquisition, she served as Alexion’s executive vice president, translational medicine. She has served as the global head of biologics of Novartis AG, senior vice president of R&D strategy and operations of Millennium Pharmaceuticals (now Takeda) and in various roles at Wyeth (now Pfizer) and Genentech, where she started her career.
Abbie is a member of the scientific advisory board for Adimab and is a current board member and the former chair of MassBio. She is also a member of the board of directors of Cedilla Therapeutics, Goldfinch Bio, Rheos Medicines, PanOptica and Flare Therapeutics.
Abbie holds a B.A. in biology from the University of California, San Diego and a Ph.D. in molecular biology from the University of Arizona.